Damora Therapeutics (DMRA) Cash from Investing Activities (2021 - 2024)
Damora Therapeutics (DMRA) posted Cash from Investing Activities of $6.0 million for Q2 2024, up 6.19% on a QoQ basis from $5.6 million in Q1 2024, and up 94.11% year-over-year from $3.1 million in Q3 2023.
Damora Therapeutics (DMRA) Cash from Investing Activities (2021 - 2024) Analysis & Trends
Damora Therapeutics' Cash from Investing Activities history runs 4 years deep, the most recent figure standing at $6.0 million for Q2 2024.
- Quarterly Cash from Investing Activities rose 94.11% year-over-year to $6.0 million in Q2 2024, while the trailing twelve-month figure through Dec 2024 was $11.6 million (down 47.83% YoY) and the FY2025 annual result came in at -$17.4 million, down 249.13% from the prior year.
- Cash from Investing Activities was $6.0 million for Q2 2024 at Damora Therapeutics, up from $5.6 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $14.4 million in Q4 2021 and bottomed at -$74.6 million in Q1 2021.
- A 4-year average of -$120285.7 and a median of $5.8 million in 2024 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2022 — Cash from Investing Activities sank 101.0% — and 2023, when it jumped 6160.78%.
- Damora Therapeutics' Cash from Investing Activities stood at $14.4 million in 2021, then fell by 0.57% to $14.3 million in 2022, then sank by 33.15% to $9.6 million in 2023, then plunged by 37.37% to $6.0 million in 2024.
- Business Quant data shows DMRA's Cash from Investing Activities at $6.0 million in Q2 2024, $5.6 million in Q1 2024, and $9.6 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,042.03 Bn | 67,041.74 Bn | - | - |
| 2 | Nanobiotix | 1,911.83 Bn | 1,911.77 Bn | - | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - | - |
| 4 | BeOne Medicines | 471.62 Bn | 466.83 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 121.97 Bn | 114.72 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 69.98 Bn | 61.22 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | - |
| 8 | Argenx Se | 55.75 Bn | 50.57 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | -25.54 Mn |
| 10 | Damora Therapeutics | 1.02 Bn | 815.09 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 6.00 Mn |
| Jun 30, 2024 | 6.00 Mn |
| Mar 31, 2024 | 5.65 Mn |
| Mar 31, 2024 | 5.65 Mn |
| Dec 31, 2023 | 9.58 Mn |
| Dec 31, 2023 | 9.58 Mn |
| Sep 30, 2023 | 8.29 Mn |
| Sep 30, 2023 | 8.29 Mn |
| Jun 30, 2023 | 3.09 Mn |
| Jun 30, 2023 | 3.09 Mn |
| Mar 31, 2023 | 1.37 Mn |
| Mar 31, 2023 | 1.37 Mn |
| Dec 31, 2022 | 14.33 Mn |
| Dec 31, 2022 | 14.33 Mn |
| Sep 30, 2022 | 8.31 Mn |
| Sep 30, 2022 | 8.31 Mn |
| Jun 30, 2022 | -51,000.00 |
| Jun 30, 2022 | -51,000.00 |
| Mar 31, 2022 | -10.21 Mn |
| Mar 31, 2022 | -10.21 Mn |